Form 4: Aprea Therapeutics Director Richard Peters Acquires Shares and Stock Options

Director Richard Peters acquired 1,045 shares of common stock and 4,185 stock options in Aprea Therapeutics on June 20, 2024.

Summary

• On June 20, 2024, Richard Peters, a director of Aprea Therapeutics, acquired 1,045 shares of common stock.
• These shares were granted as restricted stock units and will vest on June 20, 2025, contingent upon continued service on the board.
• Peters also acquired 4,185 stock options with an exercise price of $4.07.
• These options vest fully on June 20, 2025, also contingent upon continued service on the board.
• Following these transactions, Peters directly owns 2,074 shares of common stock and 4,185 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock and option grants to a company director, which is a common practice.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.

Risks

• The vesting of the restricted stock units and stock options is contingent upon continued service on the board, which introduces a dependency on Peters' continued involvement.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting conditions of the stock and options.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in the beneficial ownership of Aprea Therapeutics' securities by a company director.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder confidence.

Key Dates